The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo
Selatogrel, a potent and reversible antagonist of the P2Y12 receptor, inhibited FeCl<sub>3</sub>-induced thrombosis in rats. Here, we report the anti-thrombotic effect of selatogrel after subcutaneous applications in guinea pigs and mice. Selatogrel inhibited platelet function only 10 mi...
Guardado en:
Autores principales: | Lydie Crescence, Markus Kramberg, Martine Baumann, Markus Rey, Sebastien Roux, Laurence Panicot-Dubois, Christophe Dubois, Markus A. Riederer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0e5782d9d234401d99bb89284b6efdf4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Nuevos anticoagulantes orales
por: Berkovits,Alejandro, et al.
Publicado: (2011) -
Distinctive Effects of Red Wine and Diet on Haemostatic Cardiovascular Risk Factors
por: MEZZANO,DIEGO
Publicado: (2004) -
The Proteoglycan Biglycan Modulates Platelet Adhesion and Thrombus Formation in a GPVI-Dependent Manner
por: Henrike Hoermann, et al.
Publicado: (2021) -
Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA
por: Wu J, et al.
Publicado: (2018) -
LYMPHOCYTE-TO PLATELET ADHERENCE IN PATIENTS WITH ERYSIPELAS
por: A. N. Emelyanova, et al.
Publicado: (2014)